Table 2 Summary of the corresponding immune-histochemistry expression of ERβ-PML-(Foxo3a/Survivin) signaling pathway components in human normal breast (n = 24) and breast cancer tissues (n = 35)
From: Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis
Normal | Foxo3a-Low | Foxo3a-High | Total | Normal | Foxo3a-Low | Foxo3a-High | Total | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
PML-Low | 0 | 0 | 0 | ERβ-Low | 0 | 0 | 0 | ||||
PML-High | 1 | 23 | 24 | ERβ-High | 0 | 24 | 24 | ||||
Total | 1 | 23 | 24 | Total | 0 | 24 | 24 | ||||
Normal | PML-Low | PML-High | Total | ||||||||
ERβ-Low | 0 | 0 | 0 | Breast Cancer | Foxo3a-Low | Foxo3a-High | Total | Breast Cancer | Foxo3a-Low | Foxo3a-High | Total |
ERβ-High | 1 | 23 | 24 | PML-Low | 21 | 1 | 27 | ERβ-Low | 16 | 11 | 27 |
Total | 1 | 23 | 24 | PML-High | 13 | 0 | 8 | ERβ-High | 6 | 2 | 8 |
Total | 34 | 1 | 35 | Total | 22 | 13 | 35 | ||||
Breast Cancer | PML-Low | PML-High | Total | Normal | Survivin-Low | Survivin-High | Total | Normal | Survivin-Low | Survivin-High | Total |
ERβ-Low | 27 | 0 | 27 | PML-Low | 1 | 4 | 5 | ERβ-Low | 0 | 0 | 0 |
ERβ-High | 7 | 1 | 8 | PML-High | 0 | 19 | 19 | ERβ-High | 5 | 19 | 24 |
Total | 34 | 1 | 35 | Total | 1 | 23 | 24 | Total | 5 | 19 | 24 |
Breast Cancer | Survivin-Low | Survivin-High | Total | Breast Cancer | Survivin-Low | Survivin-High | Total | ||||
PML-Low | 0 | 0 | 27 | ERβ-Low | 0 | 27 | 27 | ||||
PML-High | 34 | 1 | 8 | ERβ-High | 0 | 8 | 8 | ||||
Total | 34 | 1 | 35 | Total | 0 | 35 | 35 |
